Menu

Javascript is not activated in your browser. This website needs javascript activated to work properly.
You are here

A novel platform for radioimmunotherapy: extracorporeal depletion of biotinylated and (90)y-labeled rituximab in patients with refractory B-cell lymphoma.

Author:
  • Ola Lindén
  • Jan Kurkus
  • Michael Garkavij
  • Eva Cavallin-Ståhl
  • Michael Ljungberg
  • Rune Nilsson
  • Tomas G Ohlsson
  • Bengt Sandberg
  • Sven-Erik Strand
  • Jan Tennvall
Publishing year: 2005
Language: English
Pages: 457-466
Publication/Series: Cancer Biotherapy & Radiopharmaceuticals
Volume: 20
Issue: 4
Document type: Journal article
Publisher: Mary Ann Liebert, Inc.

Keywords

  • Cancer and Oncology

Other

Published
  • ISSN: 1557-8852
Sven-Erik Strand
E-mail: sven-erik [dot] strand [at] med [dot] lu [dot] se

Project manager

Systemic Radiation Therapy Group

32

Professor emeritus

Medical Radiation Physics, Lund

32